A Phase I Open-Label Dose Escalation Study to Assess the Safety and Tolerability of AZD2171 Following Multiple Oral Doses in Subjects With Advanced Prostate Cancer.
Phase of Trial: Phase I
Latest Information Update: 20 Jan 2011
At a glance
- Drugs Cediranib (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors AstraZeneca
- 20 Jan 2011 Actual initiation date (Mar 2004) added as reported by ClinicalTrials.gov.
- 11 Sep 2008 New trial record.